RE: what's the state of play?13 May 2020 09:10
Interesting to take a slightly broader view and consider what might be going on out of sight. After all, Covidity shows all the hallmarks of an innovative platform with credibility and great potential, and we are now talking at worst of a raise from a position of strength, or better still a successful application for non dilutive funding from elsewhere on potential of this rapidly evolved platform. Both scenarios are possible from the TD report. Yet it was so recently we were asked with determined pessimism by a would be expert 'why would an early stage oncology company be impacted by money flowing into Covid?'
I think the moral here is to remain aware that scancell may frustrate at times financially, but scientifically it retains great capacity to surprise and imo they are very busy in both those areas. We shall see.